Genetic targeting of sprouting angiogenesis using Apln-CreER

Nature Communications

Volumn 6, Issue , 2015, Pages

  Liu, Qiaozhen ^a   Hu, Tianyuan ^a,b   He, Lingjuan ^a   Huang, Xiuzhen ^a   Tian, Xueying ^a   Zhang, Hui ^a   He, Liang ^a   Pu, Wenjuan ^a   Zhang, Libo ^a   Sun, Heng ^a   Fang, Jing ^a   Yu, Ying ^a   Duan, Shengzhong ^a   Hu, Chaobo ^c   Hui, Lijian ^c   Zhang, Haibin ^d   Quertermous, Thomas ^e   Xu, Qingbo ^f   Red Horse, Kristy ^e   Wythe, Joshua D ^g   Zhou, Bin ^a,c   more..

^a UNIVERSITY OF CHINESE ACADEMY OF SCIENCES   (China)

^b UNIVERSITY OF BONN   (Germany)

^c INSTITUTE OF GEOLOGY AND GEOPHYSICS   (China)

^d SECOND MILITARY MEDICAL UNIVERSITY   (China)

^e STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f KING'S COLLEGE LONDON   (United Kingdom)

^g BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APELIN; TAMOXIFEN; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 2; ADIPOCYTOKINE; APLN PROTEIN, MOUSE; SIGNAL PEPTIDE; VASCULOTROPIN A;

BLOOD SYSTEM DISORDER; DEVELOPMENTAL BIOLOGY; EMBRYONIC DEVELOPMENT; GENE EXPRESSION; GENETIC ANALYSIS; RODENT; SIGNALING; TUMOR;

ADULT; AGED; ALLELE; ANGIOGENESIS; ANIMAL CELL; ARTICLE; CONTROLLED STUDY; DEVELOPMENTAL BIOLOGY; ENDOTHELIUM CELL; FEMALE; GAIN OF FUNCTION MUTATION; GENE TARGETING; HOMEOSTASIS; HUMAN; IN VIVO STUDY; ISCHEMIA; LOSS OF FUNCTION MUTATION; MALE; MOUSE; NEWBORN; NONHUMAN; PROTEIN EXPRESSION; SPROUTING; TISSUE REGENERATION; TUMOR GROWTH; TUMOR VASCULARIZATION; VASCULAR DISEASE; VASCULARIZATION; ANIMAL; GENETICS; HINDLIMB; METABOLISM; PHYSIOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL LINE;

MUS;

ADIPOKINES; ANIMALS; CELL LINE, TUMOR; ENDOTHELIAL CELLS; FEMALE; HINDLIMB; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; ISCHEMIA; MALE; MICE; NEOVASCULARIZATION, PHYSIOLOGIC; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 84923108402     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms7020     Document Type: Article

References (52)

1. Carmeliet, P. Blood vessels and nerves: common signals, pathways and diseases. Nat. Rev. Genet. 4, 710-720 (2003).
2. Carmeliet, P. Angiogenesis in life, disease and medicine. Nature 438, 932-936 (2005).
3. Kusumbe, A. P., Ramasamy, S. K. & Adams, R. H. Coupling of angiogenesis and osteogenesis by a specific vessel subtype in bone. Nature 507, 323-328 (2014).
4. Ramasamy, S. K., Kusumbe, A. P., Wang, L. & Adams, R. H. Endothelial Notch activity promotes angiogenesis and osteogenesis in bone. Nature 507, 376-380 (2014).
5. Gerber, H. et al. VEGF is required for growth and survival in neonatal mice. Development 126, 1149-1159 (1999).
6. Kisanuki, Y. et al. Tie2-Cre transgenic mice: a new model for endothelial cell-lineage analysis in vivo. Dev. Biol. 230, 230-242 (2001).
7. Alva, J. et al. VE-Cadherin-Cre-recombinase transgenic mouse: a tool for lineage analysis and gene deletion in endothelial cells. Dev. Dyn. 235, 759-767 (2006).
8. Monvoisin, A. et al. VE-cadherin-CreERT2 transgenic mouse: a model for inducible recombination in the endothelium. Dev. Dyn. 235, 3413-3422 (2006).
9. Lee, S. et al. Autocrine VEGF signaling is required for vascular homeostasis. Cell 130, 691-703 (2007).
10. Wang, Y. et al. Ephrin-B2 controls VEGF-induced angiogenesis and lymphangiogenesis. Nature 465, 483-486 (2010).
11. Gustafsson, E., Brakebusch, C., Hietanen, K. & Fassler, R. Tie-1-directed expression of Cre recombinase in endothelial cells of embryoid bodies and transgenic mice. J. Cell. Sci. 114, 671-676 (2001).
12. Sheikh, A. et al. In vivo genetic profiling and cellular localization of apelin reveals a hypoxia-sensitive, endothelial-centered pathway activated in ischemic heart failure. Am. J. Physiol. Heart. Circ. Physiol. 294, H88-H98 (2008).
13. Chng, S. C., Ho, L., Tian, J. & Reversade, B. ELABELA: a hormone essential for heart development signals via the apelin receptor. Dev. Cell 27, 672-680 (2013).
14. Pauli, A. et al. Toddler: an embryonic signal that promotes cell movement via Apelin receptors. Science 343, 1248636 (2014).
15. Quertermous, T. Apelin and its g protein-coupled receptor regulate cardiac development as well as cardiac function. Dev. Cell 12, 319-320 (2007).
16. Scott, I. et al. The g protein-coupled receptor agtrl1b regulates early development of myocardial progenitors. Dev. Cell 12, 403-413 (2007).
17. Zeng, X., Wilm, T., Sepich, D. & Solnica-Krezel, L. Apelin and its receptor control heart field formation during zebrafish gastrulation. Dev. Cell 12, 391-402 (2007).
18. Kuba, K. et al. Impaired heart contractility in Apelin gene-deficient mice associated with aging and pressure overload. Circ. Res. 101, e32-e42 (2007).
19. Sato, T. et al. Apelin is a positive regulator of ACE2 in failing hearts. J. Clin. Invest. 123, 5203-5211 (2013).
20. Eyries, M. et al. Hypoxia-induced apelin expression regulates endothelial cell proliferation and regenerative angiogenesis. Circ. Res. 103, 432-440 (2008).
21. Tempel, D. et al. Apelin enhances cardiac neovascularization after myocardial infarction by recruiting aplnr θ circulating cells. Circ. Res. 111, 585-598 (2012).
22. Kalin, R. et al. Paracrine and autocrine mechanisms of apelin signaling govern embryonic and tumor angiogenesis. Dev. Biol. 305, 599-614 (2007).
23. Kidoya, H. et al. The apelin/APJ system induces maturation of the tumor vasculature and improves the efficiency of immune therapy. Oncogene 31, 3254-3264 (2012).
24. Tian, X. et al. Subepicardial endothelial cells invade the embryonic ventricle wall to form coronary arteries. Cell Res. 23, 1075-1090 (2013).
25. Tian, X. et al. De novo formation of a distinct coronary vascular population in neonatal heart. Science 345, 90-94 (2014).
26. Alitalo, K., Tammela, T. & Petrova, T. Lymphangiogenesis in development and human disease. Nature 438, 946-953 (2005).
27. Baluk, P. et al. Functionally specialized junctions between endothelial cells of lymphatic vessels. J. Exp. Med. 204, 2349-2362 (2007).
28. Jain, R. & Carmeliet, P. SnapShot: tumor angiogenesis. Cell 149, 1408-1408.e1401 (2012).
29. Muzumdar, M., Tasic, B., Miyamichi, K., Li, L. & Luo, L. A global double-fluorescent Cre reporter mouse. Genesis 45, 593-605 (2007).
30. Bard-Chapeau, E. A. et al. Ptpn11/Shp2 acts as a tumor suppressor in hepatocellular carcinogenesis. Cancer Cell 19, 629-639 (2011).
31. Maxwell, I. H., Maxwell, F. & Glode, L. M. Regulated expression of a diphtheria toxin A-chain gene transfected into human cells: possible strategy for inducing cancer cell suicide. Cancer Res. 46, 4660-4664 (1986).
32. Ivanova, A. et al. In vivo genetic ablation by Cre-mediated expression of diphtheria toxin fragment A. Genesis. 43, 129-135 (2005).
33. Carmeliet, P. et al. Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. Nature 380, 435-439 (1996).
34. Loges, S., Mazzone, M., Hohensinner, P. & Carmeliet, P. Silencing or fueling metastasis with VEGF inhibitors: antiangiogenesis revisited. Cancer Cell 15, 167-170 (2009).
35. Muhlner, U. et al. Formation of transformed endothelial cells in the absence of VEGFR-2/Flk-1 by Polyoma middle T oncogene. Oncogene 18, 4200-4210 (1999).
36. Haigh, J. et al. Cortical and retinal defects caused by dosage-dependent reductions in VEGF-A paracrine signaling. Dev. Biol. 262, 225-241 (2003).
37. von Gise, A. et al. YAP1, the nuclear target of Hippo signaling, stimulates heart growth through cardiomyocyte proliferation but not hypertrophy. Proc. Natl Acad. Sci. USA 109, 2394-2399 (2012).
38. Paez-Ribes, M. et al. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 15, 220-231 (2009).
39. Chan, D. et al. Tumor vasculature is regulated by PHD2-mediated angio-genesis and bone marrow-derived cell recruitment. Cancer Cell 15, 527-538 (2009).
40. Welti, J., Loges, S., Dimmeler, S. & Carmeliet, P. Recent molecular discoveries in angiogenesis and antiangiogenic therapies in cancer. J. Clin. Invest. 123, 3190-3200 (2013).
41. Ebos, J. M. & Kerbel, R. S. Antiangiogenic therapy: impact on invasion, disease progression, and metastasis. Nat. Rev. Clin. Oncol. 8, 210-221 (2011).
42. Miles, D. et al. Disease course patterns after discontinuation of bevacizumab: pooled analysis of randomized phase III trials. J. Clin. Oncol. 29, 83-88 (2011).
43. Singh, M. et al. Anti-VEGF antibody therapy does not promote metastasis in genetically engineered mouse tumour models. J. Pathol. 227, 417-430 (2012).
44. Seaman, S. et al. Genes that distinguish physiological and pathological angiogenesis. Cancer Cell 11, 539-554 (2007).
45. Hayman, S. R., Leung, N., Grande, J. P. & Garovic, V. D. VEGF inhibition, hypertension, and renal toxicity. Curr. Oncol. Rep. 14, 285-294 (2012).
46. Chung, A. S. & Ferrara, N. Developmental and pathological angiogenesis. Annu. Rev. Cell. Dev. Biol. 27, 563-584 (2011).
47. von Minckwitz, G. et al. Neoadjuvant chemotherapy and bevacizumab for HER2-negative breast cancer. New Engl. J. Med. 366, 299-309 (2012).
48. Miquerol, L., Gertsenstein, M., Harpal, K., Rossant, J. & Nagy, A. Multiple developmental roles of VEGF suggested by a LacZ-tagged allele. Dev. Biol. 212, 307-322 (1999).
49. Madisen, L. et al. A robust and high-throughput Cre reporting and characterization system for the whole mouse brain. Nat. Neurosci. 13, 133-140 (2010).
50. Zhou, B. et al. Adult mouse epicardium modulates myocardial injury by secreting paracrine factors. J. Clin. Invest. 121, 1894-1904 (2011).
51. Li, S., Zhou, B. & Han, Z. Therapeutic neovascularization by transplantation of mobilized peripheral blood mononuclear cells for limb ischemia. A comparison between CD34 + and CD34- mononuclear cells. Thromb. Haemost. 95, 301-311 (2006).
52. Zhou, B. et al. G-CSF-mobilized peripheral blood mononuclear cells from diabetic patients augment neovascularization in ischemic limbs but with impaired capability. J. Thromb. Haemost. 4, 993-1002 (2006).